Chapter 1. Analytical Issues Affecting the Clinical Performance of
Cardiac Troponin Assays -
Alan H.B. Wu, PhD.
Chapter 2. Prepare To Meet Your Markers: Making the Most out of
Troponin I Degradation - Jason L. McDonough, BSc(H), Ralf
Labugger, MSc, and Jennifer E. Van Eyk, PhD.
Chapter 3. Functional Sensitivity of Cardiac Troponin Assays and
its Implications for Risk-Stratification for Patients with Acute
Coronary Syndromes - Kiang-Teck J. Yeo, PhD, Kelly S.
Quinn-Hall, MT, Stephanie W. Bateman, BA, George A. Fischer, PhD,
Stacey Wieczorek, PhD, and Alan H.B. Wu, PhD.
.
Chapter 4. Report on a Survey of Analytical and Clinical
Characteristics of Commercial Cardiac Troponin Assays - Fred S.
Apple, PhD, Jesse E. Adams III, MD, Alan H.B. Wu, PhD, and Allan S.
Jaffe, MD.
Chapter 5. The Current Assessment of Qualitative and
Quantitative Point-of-Care Testing of Cardiac Markers - Roland
Valdes, Jr, PhD and Saeed A. Jortani, PhD.
Chapter 6. Acute Coronary Syndromes: Pathophysiology, Clinical
Presentation, and Initial Diagnostic Strategies - Jesse E. Adams
III, MD and Vickie A. Miracle, RN, EdD.
Chapter 7. WHO Criteria: Where Do We Go from Here? - Allan S.
Jaffe, MD.
Chapter 8. An Integrated Diagnostic Approach to the Patient with
Chest Pain - Robert L. Jesse, MD, PhD and Michael C. Kontos,
MD.
Chapter 9. The Use of Cardiac Markers for Therapeutic Decisions
in Acute Coronary Syndromes - Michael P. Hudson, MD, Britta U.
Goldmann, MD, E. Magnus Ohman, MD.
Chapter 10. The Evaluation of Acute Coronary Syndrome in the
Emergency Department: The Impact of Cardiac Biomarkers and
ST-Segment Trend Monitoring - David A. Grundy, MD and W. Brian
Gibler, MD.
Chapter 11. Cardiac Troponin T in Coronary Artery Disease: Where
Do We Stand? Evangelos Giannitsis, MD, Britta Weidtmann, MD,
Margit Muller-Bardorff, MD, Norbert Frey, MD, and Hugo A.
Katus, MD.
Chapter 12. Creatine Kinase: A Marker for the Early Diagnosis of
Acute Myocardial Infarction - Robert Fromm, MD, MPH and Robert
Roberts, MD.
Chapter 13. Fatty Acid Binding Protein as a Plasma Marker for
the Early Assessment of Individuals with Acute Coronary Syndromes -
Jan F.C. Glatz, PhD and Wim T. Hermens, PhD.
Chapter 14. Oxidized Low-Density Lipoprotein and
Malondialdehyde-Modified Low-Density Lipoprotein: Markers of
Coronary Artery Disease - Paul Holvoet, PhD, Frans Van de Werf,
MD, PhD, Johan Vanhaecke, MD, PhD, and Desire Collen, MD,
PhD.
Chapter 15. High-Sensitivity C-Reactive Protein: A Novel
Inflammatory Marker for Predicting the Risk of Coronary Artery
Disease - Paul M. Ridker, MD, MPH.
Chapter 16. Nuclear Factor Kappa B: A Marker of Coronary Artery
Disease Activity? - George K. Daniel, MD, Richa Gupta, MD,
Jessica Gillespie, BS, Rose Felten, BS, Linda Cise, MS, Kathy
Sturdevant, BS, and Michael E. Ritchie, MD.
Chapter 17. The Use of Troponins to Detect Cardiac Injury after
Cardiac and Noncardiac Surgery - Jesse E. Adams III, MD.
Chapter 18. The Role of Cardiac Troponin Testing in Renal
Disease - Fred S. Apple, PhD.
.
Chapter 19. The Use of Cardiac Biomarkers for the Detection of
Drug-Induced Myocardial Damage - Eugene H. Herman, PhD and V.J.
Ferrans, MD, PhD.
Chapter 20. The Utility of Brain Natriuretic Peptides in
Patients with Heart Failure and Coronary Artery Disease -
Johannes Mair, MD
